Vaš brskalnik ne omogoča JavaScript!
JavaScript je nujen za pravilno delovanje teh spletnih strani. Omogočite JavaScript ali pa uporabite sodobnejši brskalnik.
Nacionalni portal odprte znanosti
Odprta znanost
DiKUL
slv
|
eng
Iskanje
Brskanje
Novo v RUL
Kaj je RUL
V številkah
Pomoč
Prijava
Potential Drug-Drug Interactions among Patients with Schizophrenia Spectrum Disorders : Prevalence, Association with Risk Factors, and Replicate Analysis in 2021
ID
Bačar, Cvetka
(
Avtor
),
ID
Nagode, Katja
(
Avtor
),
ID
Pišlar, Mitja
(
Avtor
),
ID
Mrhar, Aleš
(
Avtor
),
ID
Grabnar, Iztok
(
Avtor
),
ID
Vovk, Tomaž
(
Avtor
)
PDF - Predstavitvena datoteka,
prenos
(941,45 KB)
MD5: D70C163DAE5EA8D6B87DAE8E9543ABC4
URL - Izvorni URL, za dostop obiščite
https://www.mdpi.com/1648-9144/59/2/284
Galerija slik
Izvleček
Background and Objectives: Patients with schizophrenia are often exposed to polypharmacotherapy, which may lead to drug—drug interactions. The aim of the study was to investigate the prevalence of potential drug—drug interactions (pDDIs) in hospitalized patients with schizophrenia spectrum disorders and to identify factors associated with pDDIs and manifested symptoms and signs. Materials and Methods: This cross-sectional observational study included 311 inpatients admitted to a psychiatric hospital. The LexiComp drug interaction program was used to identify pDDIs in 2014. Factors associated with the prevalence of pDDIs and factors related to clinically observed symptoms and signs were assessed using multivariable regression. In addition, replicate analysis of pDDI was performed using 2021 program updates. Results: The prevalence of pDDIs was 88.7%. Our study showed that more than half of the patients received at least one drug combination that should be avoided. The most common pDDIs involved combinations of two antipsychotics or combinations of antipsychotics and benzodiazepines, which can lead to cardio-respiratory depression, sedation, arrhythmias, anticholinergic effects, and neuroleptic malignant syndrome. The number of prescribed drugs was a risk factor for pDDIs (OR 2.85; 95% CI 1.84–5.73). All groups of clinically observed symptoms and signs were associated with the number of drugs. In addition, symptoms and signs characteristic of the nervous system and psychiatric disorders were associated with antipsychotic dosage (IRR 1.33; 95% CI 1.12–1.58), which could contribute to the development of extrapyramidal syndrome, insomnia, anxiety, agitation, and bipolar mania. The 2021 version of the drug interaction program showed a shift in drug interactions toward a lower risk rating, implying less severe patient management and possibly less alert fatigue. Conclusions: Patients with schizophrenia spectrum disorders are at high risk of developing drug—drug interactions. Optimization of drug therapy, patient monitoring, and use of drug interaction programs could help to prevent pDDIs and subsequent adverse drug events.
Jezik:
Angleški jezik
Ključne besede:
potential drug—drug interactions
,
schizophrenia
,
antipsychotics
,
drug interaction program
,
symptoms and signs
,
risk factors
Vrsta gradiva:
Članek v reviji
Tipologija:
1.01 - Izvirni znanstveni članek
Organizacija:
FFA - Fakulteta za farmacijo
Status publikacije:
Objavljeno
Različica publikacije:
Objavljena publikacija
Leto izida:
2023
Št. strani:
13 str.
Številčenje:
Vol. 59, iss. 2, art. 284
PID:
20.500.12556/RUL-144168
UDK:
615.214:616.895.8
ISSN pri članku:
1648-9144
DOI:
10.3390/medicina59020284
COBISS.SI-ID:
140427011
Datum objave v RUL:
02.02.2023
Število ogledov:
932
Število prenosov:
69
Metapodatki:
Citiraj gradivo
Navadno besedilo
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Kopiraj citat
Objavi na:
Gradivo je del revije
Naslov:
Medicina
Založnik:
MDPI
ISSN:
1648-9144
COBISS.SI-ID:
6754623
Licence
Licenca:
CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:
http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:
To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
Sekundarni jezik
Jezik:
Slovenski jezik
Ključne besede:
možne interakcije med zdravili
,
abdominalni stent-graft
,
program medsebojnega delovanja zdravil
,
simptomi in znaki
,
dejavniki tveganja
Projekti
Financer:
ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
Številka projekta:
P1-0189-2018
Naslov:
Farmacevtska tehnologija: od dostavnih sistemov učinkovin do terapijskih izidov zdravil pri otrocih in starostnikih
Podobna dela
Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:
Nazaj